98%
921
2 minutes
20
Introduction: Chronic kidney disease (CKD) is a growing global health problem driven by aging and the rise of comorbidities, including diabetes and hypertension. Although clinical and economic burdens have been reported, there is a lack of information on the multidimensional impact of CKD across countries with varying demographics and health system archetypes.
Methods: The validated IMPACT CKD model was used to project the clinical, health care resource use (HCRU), economic, patient, societal, and environmental burden of CKD in 8 countries (Australia, Brazil, China, Germany, Netherlands, Spain, United Kingdom, and United States) over 10 years (baseline: 2022; simulated years: 2023-2032).
Results: By 2032, 11.7% to 16.5% of the countries' populations were projected to have CKD, with prevalence rising in 7 countries over 10 years, and a shift toward later stages. These increases were accompanied by projected increases of 3.6% to 170.8% and 41.9% to 80.1% in the number of patients living on dialysis and with a functioning kidney transplant, respectively. Driven by this growing clinical burden, increases of over 19% in CKD costs and 20% in kidney replacement therapy (KRT) costs were projected across all countries. Impaired work productivity led to significant projected losses in gross domestic product, full-time equivalents, and tax revenue. Freshwater consumption, fossil fuel depletion, and carbon production in patients on KRT were projected to increase by over 11% in all the countries.
Conclusion: This study demonstrates the multifaceted burden of CKD globally and supports the adoption of policies such as CKD screening programs and public health awareness to promote early diagnosis and treatment to mitigate the growing disease burden.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12266219 | PMC |
http://dx.doi.org/10.1016/j.ekir.2025.03.051 | DOI Listing |
Clin Kidney J
September 2025
Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Background: Steroidal mineralocorticoid receptor antagonists (MRAs), including spironolactone, effectively treat resistant hypertension, reduce proteinuria and lower mortality in heart failure with reduced ejection fraction. However, their long-term effects in chronic kidney disease (CKD) remain unclear. This study investigated spironolactone's impact on end-stage renal disease (ESRD), major adverse cardiovascular events (MACE), hyperkalemia and mortality in CKD patients.
View Article and Find Full Text PDFAnn Neurosci
September 2025
Department of Pediatrics, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Background: Children with chronic kidney disease (CKD) are at risk of inferior neurocognitive outcomes. As the brain develops rapidly during the early years of life, we wanted to find out the impact of CKD on neurocognition when it occurs during this time and any disease-associated risk factors.
Methods: A cross-sectional case-control study was conducted in the Paediatric Nephrology Clinic, PGIMER, Chandigarh.
Curr Opin Endocrinol Diabetes Obes
September 2025
Department of Endocrinology, Bharti Hospital, Karnal, India; University Centre for Research & Development, Chandigarh University, Mohali, India.
Purpose Of Review: Obesity is a global health concern and is intricately linked to cardiovascular disease and metabolic disorders. While its causal association with chronic kidney disease (CKD) has also been recognized, this entity has not been discussed extensively. Obesity-related glomerulopathy (ORG) is pathologically a secondary form of focal segmental glomerulosclerosis (FSGS), which typically presents clinically with subnephrotic proteinuria, and histopathologically as glomerulomegaly, and the perihilar variant of FSGS.
View Article and Find Full Text PDFRen Fail
December 2025
Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Large language models (LLMs) represent a transformative advance in artificial intelligence, with growing potential to impact chronic kidney disease (CKD) management. CKD is a complex, highly prevalent condition requiring multifaceted care and substantial patient engagement. Recent developments in LLMs-including conversational AI, multimodal integration, and autonomous agents-offer novel opportunities to enhance patient education, streamline clinical documentation, and support decision-making across nephrology practice.
View Article and Find Full Text PDFJ Mol Histol
September 2025
Ultrasonography Department, Jinjiang Municipal Hospital (Shanghai Sixth People's Hospital Fujian), Quanzhou, 362200, China.
Renal ischemic disease represents a severe clinical pathological condition commonly observed in acute kidney injury (AKI), renal transplantation, and kidney surgery. It leads to renal tubular epithelial cell damage, inflammatory responses, and cell death, potentially progressing to chronic kidney disease (CKD) or even renal failure, significantly impairing patients' quality of life and survival rates. Current therapeutic strategies for renal ischemia-reperfusion injury (IRI) include pharmacological interventions, cell therapy, and gene therapy, yet their efficacy remains limited and may be accompanied by adverse effects.
View Article and Find Full Text PDF